Enbrel Liquid Immunogenicity Protocol

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the antibody formation to Enbrel liquid in subjects with Rheumatoid Arthritis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Collaborator: Immunex Corporation
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• 18 years of age or older

• Must be able to self-inject or have someone who can do so for them

• Should have Rheumatoid Arthritis per ARA criteria and screening lab results per predefined value

Exclusion Criteria:

• Any prior biologic therapy for inflammatory disease

• Any prior cyclophosphamide therapy

• Not using adequate contraception

• Pregnant or breast-feeding or any significant concurrent medical condition